Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer-Reference-Cited by-同舟云学术

Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer

Published:2015-09-15 Issue:1 Volume:122 Page:78-83
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Mahal Brandon A.¹,Aizer Ayal A.²,Efstathiou Jason A.³,Nguyen Paul L.²

Affiliation:

1. Department of Internal Medicine; Brigham and Women's Hospital; Boston Massachusetts

2. Department of Radiation Oncology; Dana-Farber Cancer Institute and Brigham and Women's Hospital; Boston Massachusetts

3. Department of Radiation Oncology; Massachusetts General Hospital; Boston Massachusetts

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference18 articles.

1. Cancer statistics, 2014;Siegel;CA Cancer J Clin.,2014

2. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer;D'Amico;JAMA.,1998

3. National Comprehensive Cancer Network Clinical practice guidelines in oncology: prostate cancer 2014 https://www.nccn.org/professionals/physician_gls/f_guidelines.asp 2013

4. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma;Genega;Mod Pathol.,2000

5. Prostate cancer detection at low prostate specific antigen;Schroder;J Urol.,2000

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostate cancer with elevated free prostate-specific antigen density: A case report;World Journal of Clinical Cases;2024-06-16

2. Reply to Borivoj Golijanin, Anthony Mega, and Dragan Golijanin’s Letter to the Editor re: Ivo I. de Vos, Sebastiaan Remmers, Renée Hogenhout, Monique J. Roobol, ERSPC Rotterdam Study Group. Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for Prostate Cancer Rotterdam. Eur Urol 2024;85:74–81;European Urology;2024-05

3. Identification of a 9-gene signature to enhance biochemical recurrence prediction in primary prostate cancer: A benchmarking study using ten machine learning methods and twelve patient cohorts;Cancer Letters;2024-04

4. Risk-stratified multi-round PSA screening for prostate cancer integrating the screening reference level and subgroup-specific progression indicators;European Journal of Medical Research;2023-07-26

5. The Transcriptomic Profiles of ESR1 and MMP3 Stratify the Risk of Biochemical Recurrence in Primary Prostate Cancer beyond Clinical Features;International Journal of Molecular Sciences;2023-05-07